News & Events Year None2019201820172016201520142013201220112009 10/17/19 REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress 10/11/19 REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting 09/30/19 REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference 09/04/19 REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 08/28/19 REGENXBIO to Present at Upcoming Investor Conferences 08/27/19 REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October 08/07/19 REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
